BR112015027249A2 - método de diagnóstico de câncer - Google Patents

método de diagnóstico de câncer

Info

Publication number
BR112015027249A2
BR112015027249A2 BR112015027249A BR112015027249A BR112015027249A2 BR 112015027249 A2 BR112015027249 A2 BR 112015027249A2 BR 112015027249 A BR112015027249 A BR 112015027249A BR 112015027249 A BR112015027249 A BR 112015027249A BR 112015027249 A2 BR112015027249 A2 BR 112015027249A2
Authority
BR
Brazil
Prior art keywords
diagnosis method
cancer diagnosis
cancer
expression
classifying
Prior art date
Application number
BR112015027249A
Other languages
English (en)
Inventor
Gieffers Christian
Fricke Harald
Sykora Jaromir
Original Assignee
Apogenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh filed Critical Apogenix Gmbh
Publication of BR112015027249A2 publication Critical patent/BR112015027249A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

resumo patente de invenção: "método de diagnóstico de câncer". a presente invenção refere-se a um método para o diagnóstico de uma doença cancerosa, compreendendo (a) determinação da expressão de cd95l em uma amostra de câncer e (b) classificação da doença de câncer de acordo com o nível de expressão de cd95l.
BR112015027249A 2013-04-29 2014-04-29 método de diagnóstico de câncer BR112015027249A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165784 2013-04-29
PCT/EP2014/058746 WO2014177576A1 (en) 2013-04-29 2014-04-29 Method of diagnosing cancer

Publications (1)

Publication Number Publication Date
BR112015027249A2 true BR112015027249A2 (pt) 2017-09-26

Family

ID=48190325

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027249A BR112015027249A2 (pt) 2013-04-29 2014-04-29 método de diagnóstico de câncer

Country Status (9)

Country Link
US (1) US20160103132A1 (pt)
EP (1) EP2992330B1 (pt)
JP (1) JP6556121B2 (pt)
CN (1) CN105393121B (pt)
AU (1) AU2014261505B2 (pt)
BR (1) BR112015027249A2 (pt)
CA (1) CA2910332A1 (pt)
MX (1) MX363679B (pt)
WO (1) WO2014177576A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2674662T3 (es) 2012-07-18 2018-07-03 Apogenix Ag Composición que comprende una mezcla de isoformas CD95-Fc
WO2015165973A1 (en) 2014-04-29 2015-11-05 Apogenix Gmbh Diagnostic anti-cd95l antibody
EP3076179A1 (en) * 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
WO2017009429A1 (en) * 2015-07-14 2017-01-19 Apogenix Ag Method of predicting the responsiveness of a cancer disease to treatment
CN118475613A (zh) * 2021-12-01 2024-08-09 Inserm(法国国家健康医学研究院) 中和抗cd95l单克隆抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003505348A (ja) * 1999-07-16 2003-02-12 マキシム ファーマシューティカルス，インコーポレイテッド 反応性酸素代謝産物阻害剤を用いた細胞傷害性リンパ球の活性化および防御
WO2003008649A1 (en) * 2001-07-20 2003-01-30 Board Of Regents, The University Of Texas System Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
AU2002336762A1 (en) * 2001-09-24 2003-04-07 Duke University Fas ligand
JP2005520523A (ja) * 2002-03-21 2005-07-14 イーライ・リリー・アンド・カンパニー アンタゴニスト的抗ｈＦａｓリガントヒト抗体およびそのフラグメント
CN101606061B (zh) * 2006-11-10 2014-01-22 阿尔法普托斯有限公司 用于检测受体配体模拟物的方法和组合物
PT2428252E (pt) * 2006-12-28 2014-12-11 Universitätsklinikum Heidelberg Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo
US20090234202A1 (en) * 2008-03-05 2009-09-17 Goix Philippe J Method and compositions for highly sensitive detection of molecules
JP5754740B2 (ja) * 2009-07-21 2015-07-29 クイーン メアリー アンド ウェストフィールド カレッジＱｕｅｅｎ Ｍａｒｙ ａｎｄ Ｗｅｓｔｆｉｅｌｄ Ｃｏｌｌｅｇｅ 細胞内薬物送達のためのｆａｓ（アポ−１，ｃｄ９５）標的化プラットフォーム
CN103874770A (zh) * 2011-08-08 2014-06-18 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
ES2674662T3 (es) * 2012-07-18 2018-07-03 Apogenix Ag Composición que comprende una mezcla de isoformas CD95-Fc

Also Published As

Publication number Publication date
WO2014177576A1 (en) 2014-11-06
JP6556121B2 (ja) 2019-08-07
JP2016524694A (ja) 2016-08-18
AU2014261505A1 (en) 2015-11-12
MX363679B (es) 2019-03-29
AU2014261505B2 (en) 2019-04-18
CN105393121A (zh) 2016-03-09
CA2910332A1 (en) 2014-11-06
CN105393121B (zh) 2018-04-24
MX2015015015A (es) 2016-07-21
EP2992330B1 (en) 2018-04-18
EP2992330A1 (en) 2016-03-09
US20160103132A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CU20160101A7 (es) Inmunoglobulina con fab en tándem
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
MX2021001659A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
BR112013006683A2 (pt) diagnóstico de câncer de mama
PH12015500480B1 (en) Antibody formulations and uses thereof
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
BR112014026661A2 (pt) método in vitro para diagnóstico e vigilância do câncer
BR112015027249A2 (pt) método de diagnóstico de câncer
BR112015019278A2 (pt) processo de elastografia multi-impulsional
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
BR112014009223A2 (pt) método para o diagnóstico da doença de niemann-pick
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
BR112015012708A2 (pt) anticorpos para bmp-6
BR112017019841A2 (pt) técnica de análise de amostra de tecido
BR112015020061A2 (pt) tratamento de câncer à base de estratificação de caix
TR201907907T4 (tr) Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri.
BR112017027304A2 (pt) método para o diagnóstico de doença de farber
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: APOGENIX AG (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements